Learning points
• In acute decompensated heart failure (ADHF), B-type natriuretic peptide (BNP) and the N-terminal proBNP appeared to retain similar increase and evolution in a heart failure with reduced ejection fraction patient treated with Sacubitril/Valsartan, suggesting that either peptide could be used to screen for ADHF with similar diagnostic performance.
Introduction
Sacubitril/Valsartan is a first-in-class combination of angiotensin receptor blocker and neprilysin inhibitor. Sacubitril/Valsartan is now recommended for the treatment of chronic heart failure with reduced ejection fraction (HFrEF) that remains symptomatic despite optimal treatment as per international guidelines. 1 In chronic HFrEF treated with Sacubitril/Valsartan, immunoreactive B-type natriuretic peptide (BNP) remained stable in the following months despite improved risk of death, while N-terminal proBNP (NT-proBNP) decreased by 20%. 2, 3 While the discrepant response of BNP and NT-proBNP was attributed to different sensitivity of the two peptides to neprilysin degradation, the increase in BNP most likely results from an increase in proBNP glycosylation 2, 4 rather than the protection of BNP from neprilysin degradation, 5 although further studies are warranted to clarify this aspect. However, the progression of BNP and NT-proBNP in patients receiving Sacubitril/Valsartan during acute decompensated heart failure (ADHF) is not known.
Timeline Case presentation
A 78-year-old Afro-Caribbean woman was hospitalized for ADHF as a consequence of a stroke. She had a history of hypertension, chronic ). Her last echocardiography, 2 years prior to presentation, found a left ventricular enddiastolic diameter (LVEDD) at 65 mm, left ventricular ejection function (LVEF) at 35%, restrictive diastolic dysfunction, pulmonary blood pressure (BP) at 55 mmHg, and an aortic and mitral insufficiency grade 2. BNP before Sacubitril/Valsartan-i.e. 3 month before her current admission-was 200 pg/mL. During the last year, she had three episodes of acute dyspnoea due to hypertension that required unplanned visits to her cardiologist without hospitalization. At the last visit, her cardiologist introduced Sacubitril/Valsartan. The introduction of Sacubitril/Valsartan occurred 3 months before her hospitalization for stroke, with an improvement in symptoms and without alteration of renal function. The patient was admitted for a right hemiplegia caused by a stroke, which provoked an abrupt rise in BP (systolic BP: 180 mmHg, diastolic BP: 110 mmHg) leading to a concomitant acute pulmonary oedema (APE). [6] [7] [8] She had hypoxaemic respiratory distress (dyspnoea, polypnoea, and crackles), and electrocardiogram showed a regular sinus rhythm without ischaemic sign confirmed by normal plasma level of high-sensitivity troponin T [9 ng/L (normal <14 ng/L)]. Chest X-ray showed bilateral alveolo-interstitial syndrome. Echocardiography showed a 25% LVEF, increased filling pressures (E/A 2.4 and E/E 0 17), known aortic and mitral insufficiency, and a LVEDD of 63 mm. At admission, measurements of immunoreactive BNP and NT-proBNP were 4208 pg/mL (normal <100 pg/mL) and 8240 pg/mL (normal <300 pg/mL), respectively. : intravenous (IV) bolus of Furosemide (80 mg) and Urapidil continuous infusion (30 mg/h) for 2 days, followed by oral intake afterwards (40 mg Furosemide once a day and 60 mg Urapidil three times a day). Dyspnoea was relieved within 2 h, allowing cerebral magnetic resonance imaging (MRI) to be performed. Cerebral MRI showed a left middle cerebral artery stroke with thrombus in this artery which was successfully treated by thrombectomy followed by treatment with acetylsalicylic acid (75 mg o.d.). Cardiac clinical symptoms improved and biology returned to baseline values, allowing discharge from intensive care unit at 6 days. Importantly, Sacubitril/Valsartan treatment was continued during hospitalization, the patient receiving 24/26 mg Sacubitril/Valsartan every morning after blood work. BNP, NT-proBNP, and circulating neprilysin (cNEP) activity were measured from samples collected every morning prior the intake of Sacubitril/Valsartan during hospitalization (Figure 1) . Both BNP and NT-proBNP were high at admission and showed paralleled decrease up to discharge. Circulating neprilysin activity remained constant and low throughout the hospitalization. The patient was then transferred to the neurology and rehabilitation department where she stayed 2 months. She was not specifically subjected to a cardiology follow-up but did not suffer from any cardiovascular event. As her neurological condition improved, she was released and follow-up stopped at this time.
Discussion
Here, we present the first case showing the evolution of BNP and NT-proBNP in ADHF in a patient receiving Sacubitril/Valsartan as her treatment for HFrEF. Both BNP and NT-proBNP retained similar values for the diagnostic of hypertensive ADHF-and probably ADHF in general-in patients treated with Sacubitril/Valsartan. Even though the patient was taking a low dose of Sacubitril/Valsartan (half the minimum dose), cNEP activity was low and below the median threshold found in patients receiving Sacubitril/Valsartan 24/26 mg b.i.d., 2 strongly suggesting the pharmacological efficacy of her treatment over a 24 h period. Of note, the pharmacological efficacy of such a low dose of Sacubitril/Valsartan could be explained by her chronic renal failure since 50% of sacubitrilate-the active metabolite of Sacubitril-is eliminated in the urine. 9 
Conclusion
In conclusion, BNP and NT-proBNP can most likely be used equivalently for the diagnostic of ADHF in patients receiving Sacubitril/Valsartan even though studies are warranted to establish whether BNP and NTproBNP retain similar diagnostic performance in this context.
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